Bill > SB1682

This bill modifies provisions related to alternative therapies and treatments, specifically focusing on psilocybin and investigational drugs. It establishes conditions under which individuals, particularly veterans and first responders, can use psilocybin for therapeutic purposes without facing state or local legal penalties, provided they have a bona fide physician-patient relationship, a diagnosed condition like PTSD or depression, are enrolled in a study, inform the Department of Mental Health, have a trained facilitator present, and ensure the psilocybin is tested and used within specific dosage limits. The bill also allows licensed laboratories to test psilocybin for these individuals and prohibits criminal or civil liability for those involved in facilitating this use, except in cases of gross negligence or willful misconduct. Furthermore, it expands the definition of an "eligible patient" for investigational drugs to include those with life-threatening or severely debilitating conditions, not just terminal illnesses, and removes the exclusion of Schedule I controlled substances from the definition of investigational drugs. The bill also mandates the Department of Mental Health to conduct a study on the efficacy of alternative therapies, including psilocybin, for veterans and first responders, and to report on its findings, while also protecting participants and healthcare providers from liability.

https://www.senate.mo.gov/26info/BTS_Web/Bill.aspx?SessionType=R&BillID=5550731